Literature DB >> 12566550

HIV viral suppression in the era of antiretroviral therapy.

H K Thaker1, M H Snow.   

Abstract

Altogether 42 million people worldwide have been infected with HIV, and 12 million have died over the last 20 years. Effective antiretroviral therapy has lead to sustained HIV viral suppression and immunological recovery in patients who have been infected with the virus. The incidence of AIDS has declined in the Western world with the introduction of effective antiretroviral therapy. Questions on When to start treatment?, What to start with?, How to monitor patients?, remain heavily debated. Adherence to antiretroviral treatment remains the cornerstone of effective treatment, and failure to adhere is the strongest predictor of virological failure. Long term therapy can lead to metabolic complications. Resource poor countries are dealing with difficult issues such as mother to child prevention of HIV transmission. Other treatment options are now available, with the recent introduction of fusion inhibitors, second generation non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors to clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566550      PMCID: PMC1742591          DOI: 10.1136/pmj.79.927.36

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  46 in total

1.  Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

Authors:  J B Angel; K G Parato; A Kumar; S Kravcik; A D Badley; C Fex; D Ashby; E Sun; D W Cameron
Journal:  J Infect Dis       Date:  2001-01-12       Impact factor: 5.226

Review 2.  The impact of highly active antiretroviral therapy on HIV-specific immune function.

Authors:  M S Saag
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

3.  The role of immunotherapy in the treatment of HIV.

Authors:  M S Saag
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

4.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

5.  Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs.

Authors:  A L Dunne; F M Mitchell; S K Coberly; N S Hellmann; J Hoy; A Mijch; C J Petropoulos; J Mills; S M Crowe
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

6.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Authors:  E Martínez; J L Blanco; J A Arnaiz; J B Pérez-Cuevas; A Mocroft; A Cruceta; M A Marcos; A Milinkovic; M A García-Viejo; J Mallolas; X Carné; A Phillips; J M Gatell
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

7.  Predictors of optimal virological response to potent antiretroviral therapy.

Authors:  W G Powderly; M S Saag; S Chapman; G Yu; B Quart; N J Clendeninn
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

8.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

9.  Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy.

Authors:  I S Fortgang; P C Belitsos; R E Chaisson; R D Moore
Journal:  Am J Gastroenterol       Date:  1995-09       Impact factor: 10.864

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  11 in total

1.  An ecosystem-based intervention to reduce HIV transmission risk and increase medication adherence among inmates being released to the community.

Authors:  Olga Grinstead Reznick; Kathleen McCartney; Steven E Gregorich; Barry Zack; Daniel J Feaster
Journal:  J Correct Health Care       Date:  2013-05-08

2.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 3.  Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Huixin Liu; Ye Ma; Yingying Su; M Kumi Smith; Ying Liu; Yantao Jin; Hongqiu Gu; Jing Wu; Lin Zhu; Ning Wang
Journal:  Clin Infect Dis       Date:  2014-07-22       Impact factor: 9.079

Review 4.  The far-reaching HAND of cART: cART effects on astrocytes.

Authors:  Hemil Gonzalez; Anthony Podany; Lena Al-Harthi; Jennillee Wallace
Journal:  J Neuroimmune Pharmacol       Date:  2020-03-09       Impact factor: 7.285

5.  HIV continuum of care in Europe and Central Asia.

Authors:  R S Drew; B Rice; K Rüütel; V Delpech; K A Attawell; D K Hales; C Velasco; A J Amato-Gauci; A Pharris; L Tavoschi; T Noori
Journal:  HIV Med       Date:  2017-01-24       Impact factor: 3.180

6.  The clinical and demographic profile of women living with HIV admitted to the acute unit at Stikland Psychiatric Hospital.

Authors:  Jean-Marie le Roux; Lina Groenewald; Karis Moxley; Liezl Koen
Journal:  South Afr J HIV Med       Date:  2021-03-16       Impact factor: 2.744

7.  Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-Saharan Africa. Evidence from panel data analysis.

Authors:  Feleke Hailemichael Astawesegn; Virginia Stulz; Elizabeth Conroy; Haider Mannan
Journal:  BMC Infect Dis       Date:  2022-02-08       Impact factor: 3.090

8.  Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.

Authors:  Hengrui Liu; Sho Iketani; Arie Zask; Nisha Khanizeman; Eva Bednarova; Farhad Forouhar; Brandon Fowler; Seo Jung Hong; Hiroshi Mohri; Manoj S Nair; Yaoxing Huang; Nicholas E S Tay; Sumin Lee; Charles Karan; Samuel J Resnick; Colette Quinn; Wenjing Li; Henry Shion; Xin Xia; Jacob D Daniels; Michelle Bartolo-Cruz; Marcelo Farina; Presha Rajbhandari; Christopher Jurtschenko; Matthew A Lauber; Thomas McDonald; Michael E Stokes; Brett L Hurst; Tomislav Rovis; Alejandro Chavez; David D Ho; Brent R Stockwell
Journal:  Nat Commun       Date:  2022-04-07       Impact factor: 17.694

9.  Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).

Authors:  Keikawus Arasteh; L Weitner; S Fenske; B Kuhlmann; M Freiwald; R Ebrahimi; L Gallo; R Ranneberg; T Mertenskoetter
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

10.  Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa.

Authors:  Claris Shoko; Delson Chikobvu
Journal:  Theor Biol Med Model       Date:  2018-07-16       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.